A structural homolog of rosiglitazone that binds PPAR&gamma with about 1/10 the affinity of rosiglitazone yet is a more potent antidiabetic agent in whole animal experiments than rosiglitazone (ED<sub>50</sub>s = 2.7 mg/kg and 7.
A structural homolog of rosiglitazone that binds PPAR&gamma with about 1/10 the affinity of rosiglitazone yet is a more potent antidiabetic agent in whole animal experiments than rosiglitazone (ED<sub>50</sub>s = 2.7 mg/kg and 7.
A potent inhibitor of B-RafV600E (Kd = 14 nM in an in vitro binding assay) blocks B-RafV600E&ndashdependent phosphorylation of MEK in human melanoma A375 and colorectal cancer COLO 205 cells (IC<sub>50</sub>s = 78 and 60 nM, respectively)
A potent inhibitor of B-RafV600E (Kd = 14 nM in an in vitro binding assay) blocks B-RafV600E&ndashdependent phosphorylation of MEK in human melanoma A375 and colorectal cancer COLO 205 cells (IC<sub>50</sub>s = 78 and 60 nM, respectively)
A small-molecule agonist of GPR40 (EC50 = 47 nM) and GPR120 (EC50 = 2.2 µM), GPCRs that are activated by medium and long-chain fatty acids potentiates glucose-stimulated insulin secretion and the KCl-mediated increase in insulin secretion in
A small-molecule agonist of GPR40 (EC50 = 47 nM) and GPR120 (EC50 = 2.2 µM), GPCRs that are activated by medium and long-chain fatty acids potentiates glucose-stimulated insulin secretion and the KCl-mediated increase in insulin secretion in
REV 5901 is an antagonist of cysteinyl-leukotriene receptors with a Ki value of 0.7 µM for guinea pig lung membranes. It is also an inhibitor of rat neutrophil 5-LO with an IC<sub>50</sub> value of 0.12 µM.
REV 5901 is an antagonist of cysteinyl-leukotriene receptors with a Ki value of 0.7 µM for guinea pig lung membranes. It is also an inhibitor of rat neutrophil 5-LO with an IC<sub>50</sub> value of 0.12 µM.
A structural homolog of rosiglitazone that binds PPAR&gamma with about 1/10 the affinity of rosiglitazone yet is a more potent antidiabetic agent in whole animal experiments than rosiglitazone (ED<sub>50</sub>s = 2.7 mg/kg and 7.
A structural homolog of rosiglitazone that binds PPAR&gamma with about 1/10 the affinity of rosiglitazone yet is a more potent antidiabetic agent in whole animal experiments than rosiglitazone (ED<sub>50</sub>s = 2.7 mg/kg and 7.
A small-molecule agonist of GPR40 (EC50 = 47 nM) and GPR120 (EC50 = 2.2 µM), GPCRs that are activated by medium and long-chain fatty acids potentiates glucose-stimulated insulin secretion and the KCl-mediated increase in insulin secretion in
A small-molecule agonist of GPR40 (EC50 = 47 nM) and GPR120 (EC50 = 2.2 µM), GPCRs that are activated by medium and long-chain fatty acids potentiates glucose-stimulated insulin secretion and the KCl-mediated increase in insulin secretion in
REV 5901 is an antagonist of cysteinyl-leukotriene receptors with a Ki value of 0.7 µM for guinea pig lung membranes. It is also an inhibitor of rat neutrophil 5-LO with an IC<sub>50</sub> value of 0.12 µM.
REV 5901 is an antagonist of cysteinyl-leukotriene receptors with a Ki value of 0.7 µM for guinea pig lung membranes. It is also an inhibitor of rat neutrophil 5-LO with an IC<sub>50</sub> value of 0.12 µM.
B-582 BradyGlo⢠is a glow-in-the-dark pressure sensitive polyester. Ideal for use in exit and directional signs, identification of fire alarms and extinguishers, and directional systems for escape or evacuations routes."
B-582 BradyGlo⢠is a glow-in-the-dark pressure sensitive polyester. Ideal for use in exit and directional signs, identification of fire alarms and extinguishers, and directional systems for escape or evacuations routes."
B-582 BradyGlo⢠is a glow-in-the-dark pressure sensitive polyester. Ideal for use in exit and directional signs, identification of fire alarms and extinguishers, and directional systems for escape or evacuations routes."
B-582 BradyGlo⢠is a glow-in-the-dark pressure sensitive polyester. Ideal for use in exit and directional signs, identification of fire alarms and extinguishers, and directional systems for escape or evacuations routes."